Wen Ting, Boyden Steven E, Hocutt Caleb M, Lewis Robert G, Baldwin Erin E, Vagher Jennie, Andrews Ashley, Nicholas Thomas J, Chapin Alexander, Fan Elaine M, Botto Lorenzo D, Bayrak-Toydemir Pinar, Mao Rong, Meznarich Jessica A
ARUP Laboratories, Salt Lake City, UT.
Department of Pathology, University of Utah, Salt Lake City, UT.
Blood Adv. 2025 May 27;9(10):2443-2452. doi: 10.1182/bloodadvances.2024015347.
Diamond-Blackfan anemia syndrome (DBAS) is a rare congenital disorder with variable penetrance and expressivity and is characterized by pure red cell aplasia that typically manifests as early-onset chronic macrocytic or normocytic anemia and is often associated with other congenital anomalies. DBAS is etiologically heterogeneous with >20 known DBAS-associated genes that encode small and large ribosomal protein subunits and an inheritance pattern that is largely autosomal dominant or sporadic. We report 2 DBAS cases with previous negative genetic testing, which included targeted gene panels, karyotype analysis, chromosome breakage analysis, and whole exome sequencing. Although clinical whole genome sequencing (WGS) was initially negative, in-depth reanalysis identified 2 novel noncoding variants in the RPS gene family, namely a maternally inherited splicing variant at the end of the first noncoding exon in RPS7 (NM_001011.4, c.-19G>C) in family 1 and a deep intronic de novo variant in RPS19 (NM_001022.4, c.172+350C>T) in family 2. In family 1, several maternal relatives were identified who shared the same variant through cascade testing; clinically, they exhibited variable degrees of anemia and elevated erythrocyte adenosine deaminase activity, a marker for DBAS. RNA sequencing analysis demonstrated deleterious functional consequences for both noncoding variants. In case 1, hematopoietic stem cell transplant with an unaffected matched sibling donor who did not carry the variant successfully cured the congenital anemia. This study identified novel noncoding variants and underscores the clinical utility of WGS in accelerating diagnosis and improving care for rare genetic disorders, particularly when timely treatment decisions are critically important.
戴蒙德-布莱克范贫血综合征(DBAS)是一种罕见的先天性疾病,其外显率和表现度各异,特征为纯红细胞再生障碍,通常表现为早发性慢性大细胞性或正常细胞性贫血,且常与其他先天性异常相关。DBAS在病因上具有异质性,已知有超过20个与DBAS相关的基因,这些基因编码小的和大的核糖体蛋白亚基,其遗传模式主要为常染色体显性或散发性。我们报告了2例先前基因检测为阴性的DBAS病例,检测包括靶向基因panel、核型分析、染色体断裂分析和全外显子测序。尽管临床全基因组测序(WGS)最初结果为阴性,但深入重新分析在RPS基因家族中发现了2个新的非编码变异,即在家族1中RPS7(NM_001011.